ESMO: European Society for Medical Oncology

  1. Lenalidomide Accord is intended for the treatment of multiple myeloma
  2. Intended change concerned both medicines in combination for first-line treatment of advanced renal cell carcinoma
  3. Approval of CCR4 directed monoclonal antibody is based on results from the Study 0761-010
  4. Gefitinib Mylan is intended for the treatment of patients with locally advanced or metastatic NSCLC with activating mutations of EGFR
  5. New indication concerns combination with bortezomib, melphalan and prednisone for the treatment of adults with newly diagnosed multiple myeloma